Effect of Treatment Naivete on MRI Outcomes with Fingolimod or Injectable Disease-Modifying Therapies in Patients with Multiple Sclerosis: PREFERMS

被引：0
|
作者：
Hunter, Samuel F. [1 ]
Thomas, Florian P. [2 ,3 ]
Meng, Xiangyi [4 ]
Schofield, Lesley [4 ]
Tenenbaum, Nadia [4 ]
Cree, Bruce A. C. [5 ]
机构：
[1] Adv Neurosci Inst, Franklin, TN USA
[2] Hackensack Univ Med Ctr, Hackensack, NJ USA
[3] Seton Hall Univ, Hackensack Meridian Sch Med, Nutley, NJ USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] UCSF Weill Inst Neurosci, San Francisco, CA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P037
引用
收藏
页码：35 / 36
页数：2
相关论文
共 50 条
  • [1] Effect of Treatment Naivete on MRI Outcomes with Fingolimod or Injectable Disease-Modifying Therapies in Patients with Multiple Sclerosis: PREFERMS
    Hunter, Samuel F.
    Thomas, Florian P.
    Meng, Xiangyi
    Schofield, Lesley
    Tenenbaum, Nadia
    Cree, Bruce A. C.
    NEUROLOGY, 2019, 92 (15)
  • [2] Effect of previous therapies on treatment retention and satisfaction in patients randomized to fingolimod or injectable disease-modifying therapies in PREFERMS
    Thomas, Florian P.
    Hunter, Samuel F.
    Meng, Xiangyi
    Schofield, Lesley
    Kolodny, Scott
    Tenenbaum, Nadia
    Cree, Bruce A. C.
    NEUROLOGY, 2018, 90
  • [3] Satisfaction and Efficacy Outcomes When Switching from Injectable Disease-Modifying Therapies to Fingolimod in PREFERMS: Effect of Previous Treatment
    Hunter, Samuel F.
    Cree, Bruce A. C.
    Meng, Xiangyi
    Schofield, Lesley
    Kolodny, Scott
    Tenenbaum, Nadia
    Thomas, Florian P. P.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 19 - 19
  • [4] Post hoc results from PREFERMS: Volumetric MRI outcomes adjusted for exposure to fingolimod versus platform injectable disease-modifying therapies in early relapsing-remitting multiple sclerosis
    Arnold, Douglas L.
    Hunter, Samuel
    Cree, Bruce
    Meng, Xiangyi
    Schofield, Lesley
    Tenenbaum, Nadia
    NEUROLOGY, 2016, 87 (02) : E24 - E24
  • [5] Cost-Effectiveness of Injectable Disease-Modifying Therapies in the Treatment of Multiple Sclerosis
    Quach, Jayson
    Dembek, Carole
    Szkurhan, Andrea
    Rashid, Nazia
    Blasco, M. R.
    NEUROLOGY, 2011, 76 (09) : A474 - A474
  • [6] PERSISTENCE TO ORAL AND INJECTABLE MULTIPLE SCLEROSIS DISEASE-MODIFYING THERAPIES
    Galaznik, A.
    Rusli, E.
    Lempernesse, B.
    Shilnikova, A.
    Ransom, J.
    Berger, M.
    VALUE IN HEALTH, 2019, 22 : S287 - S287
  • [7] Fostering adherence to injectable disease-modifying therapies in multiple sclerosis
    Lugaresi, Alessandra
    Rottoli, Maria Rosa
    Patti, Francesco
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2014, 14 (09) : 1029 - 1042
  • [8] Key Results fro PREFERMS: Real-World Patient Retention and Outcomes on Fingolimod versus Platform Injectable Disease-Modifying Therapies in Early Relapsing-Remitting Multiple Sclerosis
    Cree, Bruce
    Wynn, Daniel
    Cascione, Mark
    Meng, Xiangyi
    Schofield, Lesley
    Tenenbaum, Nadia
    NEUROLOGY, 2016, 86
  • [9] Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis
    Earla, Jagadeswara R.
    Hutton, George J.
    Thornton, Douglas J.
    Chen, Hua
    Johnson, Michael L.
    Aparasu, Rajender R.
    PHARMACOTHERAPY, 2021, 41 (05): : 440 - 450
  • [10] Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis
    Eagle, Tessa
    Stuart, Fiona
    Chua, Alicia S.
    LaRussa, Allison
    Leclaire, Kaitlynne
    Cook, Sandra L.
    Chitnis, Tanuja
    Weiner, Howard L.
    Glanz, Bonnie I.
    Healy, Brian C.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 18 : 196 - 201
12345